NCT02751710

Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 369 (actual)
• Sponsor: Ontario Clinical Oncology Group (OCOG) · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This trial is being conducted to determine the impact of whole body FDG PET-CT vs. conventional staging in the management of patients presenting with clinical Stage III breast cancer. Eligible consenting patients with ductal or mixed histology breast cancer will be randomized 1:1 to whole body FDG PET-CT or conventional staging. Eligible consenting patients with lobular only histology will be entered into a separate single arm prospective study and will undergo whole body FDG PET-CT, CT with contrast of the chest/abdomen \& pelvis and a bone scan.

Conditions

• Stage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4)
• Stage IIb Breast Cancer (T3N0)

Interventions

Type	Name	Description
OTHER	Whole-body FDG PET-CT alone	FDG PET-CT imaging

Timeline

• Start date: 2016-12-06
• Primary completion: 2023-03-31
• Completion: 2023-03-31
• First posted: 2016-04-26
• Last updated: 2024-01-19

Locations

6 sites across 1 country: Canada